Chinese Pharmaceutical Market 2012-2022

NEW YORK, Jan. 30, 2012  /PRNewswire/ --  Reportlinker.com announces that a new market research report is available in its catalogue:

Chinese Pharmaceutical Market 2012-2022

http://www.reportlinker.com/p0151197/Chinese-Pharmaceutical-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

Where is the pharma market in China heading? Visiongain's report shows you its potential revenues to 2022, discussing opportunities and developments.

Discover sales predictions at overall market and submarket levels. Our study gives you business research, analysis and opinion for drug sales in China. Find data and trends there. 

See how Chinese submarkets can perform to 2022 - patented brands, generics, OTC products, traditional medicines, anti-infectives, vaccines, cardiovascular/cerebrovascular, alimentary/metabolic, cancer and CNS drugs. You view potential revenues, with discussions. 

How will governmental reform of the healthcare system affect the pharmaceutical industry? Will patented branded products achieve greater market penetration this decade? 

Opportunities multiply. The government's Healthy China 2020 plan will mean up to $1.4 trillion invested. See the effects of rising purchase power and widening medical coverage, discovering prospects from 2012. You find information, calculations and views in this report.

Medical R&D in China is gaining prominence. Assess the trends behind its emergence as a biopharmaceutical hub, reviewing progress in outsourced research and manufacturing.

The report discusses many domestic companies, such as China National Biotec Group, Sinopharm, WuXi AppTec, Sinovac Biotech and Beijing Pharmaceutical Group. Biopharma industry is flourishing.

View activities of multinationals too, including Pfizer, Sanofi, Bayer, AstraZeneca, Roche, Novartis, GSK, Merck, Eli Lilly and Novo Nordisk. This is the country to watch for developments in healthcare. Our investigation shows you why.

Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In the report, you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), opinions and news. You receive 72 tables and charts and two research interviews.

Advantages of Chinese Pharmaceutical Market 2012-2022 for your work

In particular, this study gives you the following knowledge and benefits:• Find revenue predictions to 2022 for the overall Chinese pharma market and submarkets, seeing revenue growth• Read sections on 40 prominent companies there, viewing developments in biotechnology and other aspects of medicine• Investigate competition and opportunities influencing sales results• Find out what will stimulate and restrain the market, affecting its growth• See emerging trends in biopharma R&D, contract research and manufacturing• Appraise therapeutic and commercial needs, as well as healthcare policy• View opinions from our survey of authorities on the sector.

There, you receive a distinctive mix of quantitative and qualitative work with independent predictions. We analyse activities and events, helping you to stay ahead.

Gain pharma business research, data and analysis for the leading emerging country

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6

Table of Contents

1.1 China: Pharmaceutical Market Review

1.2 Contents of this Report 

1.3 Research and Analysis Methods

2. Chinese Pharmaceutical Market: An Overview2.1 China: National Overview2.1.1 China's Rise as an Economic Superpower2.2 From Maoism to Market: Chinese Healthcare Since World War II2.2.1 Socialised Healthcare2.2.2 Developments Since 19922.2.3 Investment, But Healthcare Disparities Remain2.3 The Rise of the Chinese Pharmaceutical Market2.3.1 Picking up the Tab2.4 Healthy China 2020: 'Unprecedented in Human History'2.4.1 Achievements and Potential of the Healthy China 2020 Initiative2.5 Demography and Disease Burden in China2.5.1 The Ageing Population2.5.2 Obesity in China2.5.3 Stroke, Heart Disease and Diabetes2.5.4 Cancer and Respiratory Diseases2.5.5 Communicable Diseases2.6 Other Aspects of the Chinese Market

3. The Chinese Pharmaceutical Market, 2012-2022

3.1 Chinese Pharmaceutical Market: Forecast, 2012-2022

3.2 The Product Mix in China, 2010

3.3 The Product Mix in China, 2012-2022

3.4 Prescribed Patented Brands: Forecast, 2012-2022

3.4.1 Drivers and Restraints for Patented Prescription Drugs

3.5 Prescribed Generics: Forecast, 2012-2022

3.5.1 Drivers and Restraints for Prescribed Generics

3.6 OTC Products: Forecast, 2012-2022

3.6.1 Drivers and Restraints for OTC Products

3.7 TCM Products: Forecast, 2012-2022

3.7.1 Drivers and Restraints for TCM Products

4. Leading Therapeutic Areas in the Chinese Market, 2012-20224.1 Anti-Infectives Market, 2012-20224.1.1 Antibiotics: China's Drugs of Choice4.1.2 Antivirals: a Growth Area 4.2 Cancer Treatments Market, 2012-20224.2.1 Small Molecules Dominate the Chinese Cancer Drug Market4.3 Cardiovascular/Cerebrovascular Market, 2012-20224.3.1 Anti-Aggregants, Statins and Vasotherapeutics4.4 Alimentary and Metabolic Diseases Market, 2012-20224.4.1 Antiulcerants and Diabetes Treatments4.5 Central Nervous System Diseases Market, 2012-20224.5.1 Pain Relief4.5.2 Anti-Depressants4.5.3 Neurodegenerative Diseases4.6 Vaccines Market, 2012-20224.6.1 Opportunities and Challenges in Vaccines 4.7 Other Therapeutic Classes Market, 2012-2022

5. China as a Pharmaceutical Hub, 2012-2022

5.1 China as a Manufacturing Hub

5.1.1 China's API Export Market

5.1.2 Contract Manufacturing Organisations: Beyond APIs

5.2 China as a Research Hub

5.2.1 Clinical Trials in China

5.2.2 The Rise of China's Contract Research Organisations

5.3 China as a Biotechnology Hub

5.3.1 Leading the Way in Biosimilars

5.3.2 Biomarkers and Genomic Sequencing

5.3.3 Stem Cells in China

5.3.4 Other Regenerative Medicine in China

5.4 China as a Pharmaceutical Hub: Conclusions

6. Key Domestic Players in the Chinese Market, 20126.1 Fragmentation and Consolidation Among Chinese Companies6.2 Summary of Leading Domestic Companies6.3 China National Pharmaceutical Corporation (Sinopharm)6.4 China National Biotec Group (CNBG)6.5 WuXi AppTec6.6 CSPC Pharmaceutical Group6.7 Beijing Pharmaceutical Group6.8 Shanghai Pharmaceutical Group (SPGC)6.9 Yangtze River Pharmaceutical Group6.10 Tianjin Pharmaceuticals Group Corporation (TJPC)6.11 Taiji Group6.12 C&O Pharmaceutical Technology Holdings6.13 Harbin Pharmaceutical Group Holding Company6.14 Guangzhou Pharmaceutical Holdings6.15 Sinovac Biotech (Beijing Kexing Bioproducts)6.16 Tongrengtang Pharmaceutical6.17 Buchang Pharmaceutical6.18 Northeast Pharmaceutical Group (NEPG)6.19 China Nepstar Chain Drugstore6.20 Zhejiang Huahai Pharmaceuticals6.21 Hangzhou Zhongmei Huadong Pharmaceutical6.22 Hualan Biological Engineering6.23 China Sky One Medical6.24 Zensun (Shanghai) Sci & Tech6.25 Ascletis6.26 Shangdong Dong-E-E-Jiao6.27 Mindray Medical International and China Medical Technologies

7. Key Multinational Players in the Chinese Market, 2012

7.1 Bayer Schering

7.2 AstraZeneca

7.3 Pfizer

7.4 Sanofi

7.5 Roche

7.6 Novartis

7.7 GlaxoSmithKline

7.8 Merck & Co.

7.9 Novo Nordisk

7.10 Eli Lilly

7.11 Abbott Laboratories

7.12 Johnson & Johnson

7.13 Bristol-Myers Squibb

7.14 Teva Pharmaceutical Industries

7.15 Takeda

8. The Chinese Pharma Market: Qualitative Analysis8.1 Strengths: Government Investment Will Further Expand this Dynamic Market8.2 Weaknesses: IP and Regulatory Challenges Remain8.3 Opportunities: The Scramble for China8.4 Threats: A House Built on Sand?

9. Research Interviews 

9.1 Interview with Dr Derek Lowe, Drug Discovery Expert

9.1.1 On the Rising Cost of Outsourcing Research to China

9.1.2 On Building Relationships in the Chinese Market

9.1.3 On Prospects for Western Brands in the Chinese Market

9.1.4 On IP Protection and Safety Concerns in China

9.1.5 On the Role of the Chinese State in the Pharmaceutical Market

9.1.6 On Biotechnology and the Chinese Research Culture

9.1.7 On Chinese Biosimilar Manufacturing

9.2 Interview with Dr Jean-Pierre Wery, President, Crown Bioscience, China

9.2.1 Contract Research Services Offered by Crown Bioscience

9.2.2 On Technological Platforms and Animal Models Relevant to Biomarkers

9.2.3 On the Range of Therapeutic Areas Covered by Crown Bioscience

9.2.4 On Translational Medicine and Patient Stratification

9.2.5 On the Future for Crown Bioscience and Other CROs

10. Conclusions10.1 The Chinese Pharma Market Will Continue to Grow Rapidly10.2 Treatments for Chronic Diseases Will Challenge the Anti-Infectives Sector10.3 China Will Continue to Grow as a Focus for the Multinational Industry10.4 China is Set to be the Most Important Pharmaceutical Market, Despite Weaknesses

List of Tables

Table 2.1 Causes of Mortality in China, 2002Table 3.1 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2010-2015Table 3.2 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2016-2022Table 3.3 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010 Table 3.4 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 3.5 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015 Table 3.6 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 3.7 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022 Table 3.8 Prescribed Patented Brands Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 3.9 Prescribed Patented Brands Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 3.10 Prescribed Generics Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 3.11 Prescribed Generics Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 3.12 OTC Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 3.13 OTC Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 3.14 TCM Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 3.15 TCM Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.1 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2010Table 4.2 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2015Table 4.4 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2022Table 4.6 Anti-Infectives Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.7 Anti-Infectives Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.8 Oncology Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.9 Oncology Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.10 Cardiovascular/Cerebrovascular Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.11 Cardiovascular/Cerebrovascular Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.12 Alimentary/Metabolic Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.13 Alimentary/Metabolic Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.14 CNS Diseases Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.15 CNS Diseases Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.16 Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.17 Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 4.18 Other Therapeutic Classes Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015Table 4.19 0ther Therapeutic Classes Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022Table 8.1 Strengths and Weaknesses in the Chinese Pharma Market, 2012-2022Table 8.2 Opportunities and Threats in the Chinese Pharma Market, 2012-2022

List of Figures

Figure 2.1 Causes of Mortality in China, 2002Figure 3.1 Chinese Pharmaceutical Market: Revenues ($bn), 2010-2015Figure 3.2 Chinese Pharmaceutical Market: Revenues ($bn), 2016-2022Figure 3.3 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010 Figure 3.4 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), 2010-2015Figure 3.5 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015 Figure 3.6 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), 2016-2022Figure 3.7 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022 Figure 3.8 Prescribed Patented Brands Market: Revenues ($bn), 2010-2015Figure 3.9 Prescribed Patented Brands Market: Revenues ($bn), 2016-2022Figure 3.10 Prescribed Generics Market: Revenues ($bn), 2010-2015Figure 3.11 Prescribed Generics Market: Revenues ($bn), 2016-2022Figure 3.12 OTC Products Market: Revenues ($bn), 2010-2015Figure 3.13 OTC Products Market: Revenues ($bn), 2016-2022Figure 3.14 TCM Products Market: Revenues ($bn), 2010-2015Figure 3.15 TCM Products Market: Revenues ($bn), 2016-2022Figure 4.1 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2010 Figure 4.2 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), 2010-2015Figure 4.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2015Figure 4.4 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), 2016-2022Figure 4.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2022Figure 4.6 Anti-Infectives Market: Revenues ($bn), 2010-2015Figure 4.7 Anti-Infectives Market: Revenues ($bn), 2016-2022Figure 4.8 Oncology Market: Revenues ($bn), 2010-2015Figure 4.9 Oncology Market: Revenues ($bn), 2016-2022Figure 4.10 Cardiovascular/Cerebrovascular Market: Revenues ($bn), 2010-2015Figure 4.11 Cardiovascular/Cerebrovascular Market: Revenues ($bn), 2016-2022Figure 4.12 Alimentary/Metabolic Market: Revenues ($bn), 2010-2015Figure 4.13 Alimentary/Metabolic Market: Revenues ($bn), 2016-2022Figure 4.14 CNS Diseases Market: Revenues ($bn), 2010-2015Figure 4.15 CNS Diseases Market: Revenues ($bn), 2016-2022Figure 4.16 Vaccines Market: Revenues ($bn), 2010-2015Figure 4.17 Vaccines Market: Revenues ($bn), 2016-2022Figure 4.18 Other Therapeutic Classes Market: Revenues ($bn), 2010-2015Figure 4.19 0ther Therapeutic Classes Market: Revenues ($bn), 2016-2022  

Companies Listed

Acambis

Agilent Technologies

American California Pharmaceutical Group

Anhui BBCA Biochemical

AppTech Laboratory Services

Ascletis

Asian Cancer Research Group

AstraZeneca

Aurobindo Pharma

AXM Pharma

Bayer Schering Pharma

Beijing Bio-Ekon Biotechnology 

Beijing Double-Crane Pharmaceutical Business 

Beijing GP Medical Technologies

Beijing Haiyan Pharmaceutical Company

Beijing Pharmaceutical Group

Beijing Shuanglu

Beijing Tiantan Biological Products

Beijing Union Medical College Hospital

Beijing University

Beijing Wandong Medical Equipment

Beijing Yuande Bio-Medical Engineering

BGI (formerly Beijing Genomics Institute)

Biocon

BioDura

BioMarin Pharmaceutical

Bioton

BMP Sandstone 

Bristol-Myers Squibb 

Broad Institute 

Buchang Pharmaceutical

C&O Pharmaceutical Technology Holdings

Cai Zhi Lin Pharmacies

Cancer Therapeutics 

Charles River Laboratories 

China Aoxing 

China Chain Stores and Franchise Association (CCSFA)

China Medical Technologies

China National Biotec Group

China National Pharmaceutical Corporation (Sinopharm)

China Nepstar Chain Drugstore 

China Pharmaceutical Group (China Pharma)

China Sky One Medical

ChinaBio Therapeutics

Chinese Academy of Medical Sciences

Chinese Academy of Sciences

Chinese Diabetes Society

Chongqing Taiji Industry Group

Chongqing Tongjunge

Cipla

Cord Blood America 

Covance

Crown Bioscience

Crucell Biotechnology 

CSPC Pharmaceutical Group 

CSPC Zhongrun

Cumencor Pharmaceuticals

Denosim

Dong-A Pharmaceutical

Dr. Reddy's Laboratories 

Eisai

Eli Lilly 

European Medicines Agency (EMEA/EMA)

Excel PharmaStudies

FeRx 

Food and Drug Administration (FDA, US)

Frontage Laboratories 

GenScript

Genzyme Corporation

GlaxoSmithKline

Goldman Sachs Group

Greater China Corporation

Guangdong Province People's Hospital

Guangzhou Medical University

Guangzhou Pharmaceutical Company

Guangzhou Pharmaceutical Holdings

Habin Tian Di Ren Medical Science and Technology 

Hangzhou Sanofi-Synthelabo Minsheng 

Hangzhou Zhongmei Huadong Pharmaceutical

Harbin Pharmaceutical Group

HD Biosciences

Hebei Pharmaceutical Group 

Huadong Medicine Company

Hualan Biological Engineering 

Hutchison MediPharma 

Institute for BioMedical Research (Shanghai)

International Diabetes Foundation 

Introgen Therapeutics

Ivax Corporation

Jian Min Pharmacies

Jiangsu Haici Biological Pharmacy Company

Jiangsu New Medicine Research Institution

Jiangsu Walvax Biotech

Johnson & Johnson 

Knoll

LEAD Pharmaceuticals

LG Life Sciences

Lundbeck

Merck & Co.

MicuRx Pharmaceuticals

Mindray Medical International 

Ministry of Commerce (China)

Ministry of Science and Technology (China)

Minsheng Pharmaceutical

Mirahi Biotech 

Nanjing Hailing National Engineering Research Center

Nanjing Hailing Pharmaceutical Company

National Center for Drug Screening (China)

New England Journal of Medicine 

Northeast General Pharmaceutical

Northeast Pharmaceutical Group (NEPG)

NorthEast Pharmacy Chain

NovaMed Pharmaceuticals

Novartis

Novartis China 

Novo Nordisk 

Nycomed Amersham

Organization for Economic Cooperation and Development (OECD)

Patheon

Pfizer

Piramal Healthcare Solutions

PlaNrt Finance

Provincial Institute for the Control of Pharmaceutical and Biologic Products (China)

Qilu Pharmaceutical

QRxPharma

Roche

Sandoz (part of Novartis)

Sanjing Pharmaceutical

Sanofi

Shandong Dong-E E-Jiao 

Shanghai Zhong Hua Pharmaceutical Factory (Jiang Qiao Branch)

Shanghai ChemExplorer 

Shanghai Haini Pharmaceutical Company

Shanghai Huai Hai Pharmaceutical Factory

Shanghai Institute for Biological Sciences 

Shanghai Institute of Materia Medica 

Shanghai Jiao Tong University

Shanghai No. 6 Pharmaceutical Factory

Shanghai Pharmaceutical Group (SPGC)

Shanghai Qisheng

Shanghai Schering-Plough 

Shanghai Sunve Pharmaceutical 

Shanghai Xin Hua Lian Pharmaceutical 

Shenzhen Neptunus Interlong Bio-Technique 

Shenzhen SiBiono GeneTech

Shijiazhuang Pharmaceutical Group 

Shire Pharmaceuticals

SiBiono

Sichuan Hairong Pharmaceutical Company

Sicor Pharmaceuticals

SiniWest Holdings 

Sino-American Kunming Baker Norton Pharmaceutical

Sinopharm

Sinovac Biotech (Beijing Kexing Bioproducts)

Solvay Pharmaceuticals

Southwest Pharmaceutical 

State Food and Drug Administration (SFDA)

State Key Lab of Respiratory Disease

Sundia Meditech

Sunway Biotech 

Suzhou Novartis Pharma Technology 

Taiji Group

Takeda Pharmaceutical 

Tangshan Yian Bioengineering

Teva Pharmaceutical Industries

Thermo Fisher Scientific

Tianjin International Joint Academy of Biotechnology and Medicine

Tianjin Jin Yao Group 

Tianjin Medical University Cancer Hospital

Tianjin Pharmaceutical Factory

Tianjin Pharmaceuticals Group Corporation 

Tianjin Takeda Pharmaceuticals

Tonghua Dongbao 

Tongrentang Pharmaceutical

Tsinghua University

UNICEF

United Pharmatech

Vertex Pharmaceuticals

Weisheng Pharmaceutical

Working Group on Obesity in China

World Health Organization (WHO)

World Trade Organization (WTO)

Wuhan National Bioindustry Base Construction

WuXi AppTec

WuXi PharmaTech 

Wyeth (now part of Pfizer)

Xian-Janssen Pharmaceuticals

Yangtze River Pharmaceutical Group 

Yunnan Walvax BiotechJiangsu Pharmaceutical Company

Zensun (Shanghai) Sci & Tech

Zhejiang Huahai Pharmaceuticals 

Zhejiang Medicine 

Zhejiang Tianyuan

Zhongnuo

Zydus Cadila 

To order this report:Drug and Medication Industry: Chinese Pharmaceutical Market 2012-2022

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker